<!DOCTYPE html>
<html lang="en" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Pediatric CHD: Valve & Conduit Innovation</title>
    <script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <!-- Chosen Palette: Calm Neutrals -->
    <!-- Application Structure Plan: The application is designed as a multi-section SPA with a sticky top navigation bar. This structure allows users to jump directly to a specific topic of interest (e.g., "Company Pipeline") or consume the report in a linear fashion. This is superior to a simple document as it handles dense, distinct topics without overwhelming the user. Key interactions include filtering the company pipeline by status and technology, hovering over the FDA pathway for details, and exploring tooltips on charts. This user-driven exploration of a complex dataset is the core design goal. -->
    <!-- Visualization & Content Choices: 
        - Report Info: Company pipeline data -> Goal: Organize/Compare -> Viz: Filterable card grid -> Interaction: Buttons to filter company cards by status/type -> Justification: Allows users to dynamically query the data and focus on relevant innovators (e.g., only clinical-stage companies). Method: HTML/Tailwind + JS.
        - Report Info: Market size projections -> Goal: Change -> Viz: Line Chart -> Interaction: Hover tooltips -> Justification: Best method to visualize growth trends over time. Library: Chart.js.
        - Report Info: FDA approval process -> Goal: Organize/Inform -> Viz: Interactive diagram -> Interaction: Hover over steps to reveal details -> Justification: Turns a static list into an engaging, explorable element without using SVG. Method: HTML/Tailwind.
        - Report Info: New approach comparisons -> Goal: Compare -> Viz: Side-by-side card layout -> Interaction: Static display -> Justification: Clearly contrasts different technology philosophies (e.g., surgical vs. transcatheter) for easy comparison. Method: HTML/Tailwind.
    -->
    <!-- CONFIRMATION: NO SVG graphics used. NO Mermaid JS used. -->
    <style>
        :root {
            --bg: #ffffff;
            --ink: #0f172a;      /* slate-900 */
            --muted: #475569;     /* slate-600 */
            --subtle: #e2e8f0;     /* slate-200 */
            --line: #e5e7eb;      /* gray-200 */
            --panel: #f8fafc;     /* slate-50 */
            --accent: #2563eb;    /* blue-600 */
        }
        html, body {
            background: var(--bg); color: var(--ink); margin:0; font-family: 'Inter', ui-sans-serif, system-ui, -apple-system, Segoe UI, Roboto, Helvetica, Arial, 'Apple Color Emoji', 'Segoe UI Emoji';
            -webkit-font-smoothing: antialiased; -moz-osx-font-smoothing: grayscale;
        }
        .wrap { max-width: 980px; margin: 0 auto; padding: 28px 18px 60px; }
        header { padding-bottom: 12px; border-bottom: 1px solid var(--line); margin-bottom: 18px; }
        h1 { font-size: 28px; line-height: 1.2; margin: 0 0 4px; font-weight: 700; }
        .subtitle { color: var(--muted); font-size: 16px; margin-bottom: 8px; }
        
        .sticky-nav { position: sticky; top: 0; z-index: 10; background: rgba(255,255,255,0.9); backdrop-filter: blur(6px); border-bottom: 1px solid var(--line); }
        .nav-container { display:flex; justify-content:center; flex-wrap:wrap; gap:6px; padding: 10px 18px; max-width: 980px; margin: 0 auto; }
        .nav-link { color: var(--muted); text-decoration:none; padding:8px 12px; border-radius:8px; border:1px solid var(--line); font-size:14px; font-weight: 500; transition: color 0.2s, background-color 0.2s, border-color 0.2s; }
        .nav-link:hover { color: var(--ink); border-color: var(--subtle); }
        .nav-link-active { color: var(--accent); border-color: #93c5fd; background-color: #eff6ff; }

        main { padding-top: 16px; }
        section { background: var(--panel); border: 1px solid var(--line); border-radius: 12px; padding: 24px; margin-top: 24px; }
        h2 { font-size: 20px; margin: 0 0 6px; text-align: center; font-weight: 700; }
        h3 { font-size: 16px; margin: 14px 0 8px; color: var(--accent); font-weight: 600; }
        p, li { color: var(--ink); font-size: 14.5px; line-height: 1.6; }
        ul { list-style-position: inside; }

        .filter-btn-group { display: flex; justify-content: center; flex-wrap: wrap; gap: 8px; margin-top: 24px; }
        .filter-btn { background-color: var(--bg); color: var(--muted); border: 1px solid var(--line); font-size: 13px; font-weight: 500; padding: 8px 16px; border-radius: 999px; cursor: pointer; transition: all 0.2s; }
        .filter-btn:hover { border-color: var(--subtle); color: var(--ink); }
        .filter-btn-active { background-color: var(--accent); color: white; border-color: var(--accent); }
        
        .company-card { background: var(--bg); border: 1px solid var(--line); border-radius: 12px; padding: 20px; transition: transform 0.2s ease-in-out, box-shadow 0.2s ease-in-out; display: flex; flex-direction: column; }
        .company-card:hover { transform: translateY(-5px); box-shadow: 0 10px 15px -3px rgb(0 0 0 / 0.07), 0 4px 6px -4px rgb(0 0 0 / 0.07); }
        .status-badge { font-size: 11px; font-weight: 600; padding: 4px 10px; border-radius: 999px; }

        .pathway-container { background: white; padding: 20px; border-radius: 12px; border: 1px solid var(--line); }
        .pathway-step-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(120px, 1fr)); gap: 8px; align-items: center; }
        .pathway-step { background-color: var(--panel); border: 1px solid var(--line); border-radius: 8px; padding: 12px; font-weight: 500; font-size: 13px; transition: all 0.2s; text-align: center; cursor: default; }
        .pathway-step:hover { border-color: var(--accent); color: var(--accent); background-color: #eff6ff; }
        #pathway-details { background: var(--panel); border-radius: 8px; padding: 16px; min-height: 80px; display: flex; align-items: center; justify-content: center; text-align: center; color: var(--muted); margin-top: 16px; }

        .chart-container { position: relative; width: 100%; margin: 24px auto 0; height: 280px; max-height: 300px; }
        .kpi-grid { display:grid; grid-template-columns: repeat(auto-fit, minmax(220px, 1fr)); gap: 12px; margin: 24px 0 2px; }
        .kpi-card { background: #fff; border:1px solid var(--line); border-radius: 12px; padding: 14px; }
        .kpi-label { color: var(--muted); font-size: 12px; }
        .kpi-value { font-size: 20px; margin-top: 2px; font-weight: 600; }
        .callout { background: #fff; border-left: 4px solid var(--accent); padding: 10px 12px; border-radius: 6px; border:1px solid var(--line); margin-top: 16px; }

        footer { text-align: center; padding: 40px 18px 20px; color: var(--muted); font-size: 12px; border-top: 1px solid var(--line); margin-top: 40px; }
        .citation { font-size: 0.75rem; color: var(--muted); font-style: italic; }
        .fade-in { animation: fadeIn 0.6s ease-in-out forwards; opacity: 0; }
        @keyframes fadeIn { from { opacity: 0; transform: translateY(20px); } to { opacity: 1; transform: translateY(0); } }
    </style>
</head>
<body>
    <div class="wrap">
        <header>
            <a href="./index.html" style="font-size:14px; text-decoration: none; color:var(--muted); margin-bottom:16px; display:inline-block;">&larr; Return to Project Index</a>
            <h1>Pediatric Congenital Heart Disease (CHD)</h1>
            <p class="subtitle">Deep Dive: Valve & Conduit Replacement Innovation</p>
        </header>

        <nav class="sticky-nav">
             <div class="nav-container">
                <a href="#standard-of-care" class="nav-link">1. Standard of Care</a>
                <a href="#new-approaches" class="nav-link">2. New Approaches</a>
                <a href="#company-pipeline" class="nav-link">3. Company Pipeline</a>
                <a href="#context" class="nav-link">4. Context & Leaders</a>
                <a href="#regulatory" class="nav-link">5. Regulatory</a>
                <a href="#market" class="nav-link">6. Market Dynamics</a>
            </div>
        </nav>

        <main>
            <section id="standard-of-care" class="fade-in">
                <h2>1. Current Standard of Care</h2>
                <p style="color: var(--muted); text-align: center; max-width: 80%; margin: 16px auto 0;">The management of pediatric CHD combines catheter-based interventions and open-heart surgery, yet is fundamentally constrained by the lack of implants that can grow with a child, leading to a cycle of re-operations.</p>
                
                <div class="grid grid-cols-1 md:grid-cols-2 gap-6 mt-8 items-start" style="display:grid; gap:24px;">
                    <div>
                        <h3>Treatment Paradigm</h3>
                        <p>Care ranges from watchful waiting to complex staged surgeries. The approach depends on the defect type. <span class="citation">(Primary: AHA/ACC Statistics 2024–2025; Secondary: Standard of Care note)</span></p>
                        <ul class="mt-4 space-y-3">
                            <li><strong>Catheter Interventions:</strong> Preferred for simpler lesions like Atrial Septal Defects (ASDs) using occluder devices, or for stenosis using balloon angioplasty.</li>
                            <li><strong>Open-Heart Surgery:</strong> The standard for complex defects like Tetralogy of Fallot (ToF) or Truncus Arteriosus, typically performed in infancy (3-6 months).</li>
                            <li><strong>Staged Reconstruction:</strong> Required for single-ventricle defects (e.g., HLHS), involving multiple planned surgeries over several years (e.g., Norwood, Glenn, Fontan procedures).</li>
                        </ul>
                    </div>
                    <div class="callout" style="border-color: #f59e0b;">
                        <h3 style="color: #b45309; margin-top:0;">Core Unmet Needs</h3>
                        <p style="color: #78350f;">The central problem driving innovation is the biological mismatch between a growing child and static implants. <span class="citation">(Primary: Congenital Heart Defect Devices Market & Trends Report 2035; Secondary: All Notes 9.2.2025)</span></p>
                        <ul class="mt-4 space-y-3" style="color: #78350f;">
                            <li><strong>Lack of Growth:</strong> Today's implants (valves, conduits, patches) do not grow. A device implanted in an infant will be outgrown, necessitating 3-5+ high-risk re-operations over a patient's lifetime.</li>
                            <li><strong>Material Degradation:</strong> Bioprosthetic tissues used in valves calcify and degenerate faster in children than in adults, leading to premature failure.</li>
                            <li><strong>"Adult-First" Devices:</strong> The market is dominated by the off-label use of adult devices, which are often poorly suited for pediatric anatomy and physiology.</li>
                        </ul>
                    </div>
                </div>
            </section>

            <section id="new-approaches" class="fade-in">
                <h2>2. New Approaches to Address Unmet Needs</h2>
                <p style="color: var(--muted); text-align: center; max-width: 80%; margin: 16px auto 0;">Innovation is focused on three key areas: developing growth-accommodating hardware, advancing materials science to create "living" tissues, and expanding the use of minimally-invasive transcatheter techniques to younger patients.</p>

                <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mt-8" style="display:grid; gap:24px;">
                    <div class="company-card">
                        <h3>Surgical vs. Transcatheter</h3>
                        <p class="mt-3"><strong class="font-semibold">Surgical:</strong> Remains the gold standard for initial, complex repairs. The focus is on creating better implants, like size-adjustable valves (Autus), that reduce future surgeries.</p>
                        <p class="mt-3"><strong class="font-semibold">Transcatheter:</strong> The dominant trend is to replace or defer surgery. This includes developing miniaturized valves (PolyVascular) and stents (Renata) suitable for neonates and infants.</p>
                    </div>
                    <div class="company-card">
                        <h3>Biological vs. Mechanical</h3>
                        <p class="mt-3"><strong class="font-semibold">Biological:</strong> The frontier is regenerative medicine. Tissue-engineered conduits (Annoviant) and polymer valves (PolyVascular) aim to be repopulated by the patient's own cells, creating a living, durable repair.</p>
                        <p class="mt-3"><strong class="font-semibold">Mechanical:</strong> This refers to traditional hardware. Innovation here focuses on smarter mechanics, such as balloon-expandable stents and adjustable valves that accommodate growth through intervention, not biology.</p>
                    </div>
                    <div class="company-card">
                        <h3>Growth-Accommodating</h3>
                        <p class="mt-3">This is the ultimate goal. Approaches include:</p>
                        <ul class="mt-2 space-y-2">
                           <li><strong>Expandable:</strong> Devices like the Renata Minima™ stent are implanted small and serially expanded via balloon catheter as the child grows.</li>
                           <li><strong>Adjustable:</strong> Devices like the Autus valve are surgically implanted and later adjusted in size non-surgically.</li>
                           <li><strong>Regenerative:</strong> The ideal solution where a bioresorbable scaffold guides the body to build its own permanent, growing tissue.</li>
                        </ul>
                    </div>
                </div>
            </section>

            <section id="company-pipeline" class="fade-in">
                <h2>3. List and Comparison of Companies</h2>
                <p style="color: var(--muted); text-align: center; max-width: 80%; margin: 16px auto 0;">The pipeline features a mix of startups targeting specific pediatric niches and established players adapting their portfolios. Filter the companies below to explore the landscape.</p>
                
                <div class="filter-btn-group">
                    <button class="filter-btn filter-btn-active" data-filter="all">All</button>
                    <button class="filter-btn" data-filter="Approved">FDA Approved/Cleared</button>
                    <button class="filter-btn" data-filter="Clinical">Clinical Stage</button>
                    <button class="filter-btn" data-filter="Pre-clinical">Pre-clinical</button>
                    <button class="filter-btn" data-filter="Valve">Valve Tech</button>
                    <button class="filter-btn" data-filter="Stent">Stent Tech</button>
                    <button class="filter-btn" data-filter="Conduit">Conduit Tech</button>
                </div>

                <div id="company-grid" class="mt-10 grid grid-cols-1 md:grid-cols-2 lg:grid-cols-3 gap-6" style="display:grid; gap:16px;">
                </div>
            </section>
            
            <section id="context" class="fade-in">
                <h2>4. Context of Disease</h2>
                <p style="color: var(--muted); text-align: center; max-width: 80%; margin: 16px auto 0;">CHD has transformed from a fatal condition to a chronic disease, driven by clinical expertise concentrated in a few elite centers and guided by key publications from major cardiological societies.</p>
                <div class="grid grid-cols-1 md:grid-cols-2 gap-6 mt-8" style="display:grid; gap:24px;">
                    <div>
                        <h3>Key Publications & Guidelines</h3>
                        <ul class="mt-4 space-y-3">
                           <li><strong>AHA/ACC & ESC Guidelines:</strong> The "2018 AHA/ACC Guideline for the Management of Adults with CHD" and the "2020 ESC Guidelines" are foundational documents that define the standard of care.</li>
                           <li><strong>Premier Journals:</strong> Seminal research is published in top-tier journals like *JACC*, *Circulation*, and the *European Heart Journal*.</li>
                           <li><strong>Epidemiological Data:</strong> Meta-analyses from sources like the CDC and in JACC by van der Linde et al. establish the prevalence (~1% of live births) and disease burden. <span class="citation">(Primary: CDC CHD data; AHA/ACC Stats 2024–2025; Secondary: All Notes 9.2.2025 (epidemiology))</span></li>
                        </ul>
                    </div>
                     <div>
                        <h3>Thought Leaders & Institutions</h3>
                        <ul class="mt-4 space-y-3">
                           <li><strong>"Super Centers":</strong> Expertise is highly concentrated. Boston Children's, Texas Children's, and CHOP (Philadelphia) are crucial hubs for clinical trials and technology validation.</li>
                           <li><strong>Funding & Advocacy:</strong> Non-dilutive funding from organizations like the NIH, Additional Ventures, and the American Heart Association (AHA) is critical for de-risking early-stage innovation.</li>
                           <li><strong>Key Opinion Leaders (KOLs):</strong> Many innovators, like the founders of Autus Valve, are leading pediatric surgeons and engineers from these top institutions.</li>
                        </ul>
                    </div>
                </div>
            </section>

            <section id="regulatory" class="fade-in">
                <h2>5. Regulatory Environment</h2>
                <p style="color: var(--muted); text-align: center; max-width: 80%; margin: 16px auto 0;">The FDA pathway for high-risk pediatric devices is complex and lengthy, favoring companies that can leverage specialized programs or provide compelling long-term durability data.</p>
                 <div class="mt-8 pathway-container">
                    <h3 class="text-center" style="margin-top:0;">Key FDA Pathways & Designations</h3>
                    <div class="pathway-step-grid mt-6">
                        <div class="pathway-step" data-step="1">1. Pre-Clinical</div>
                        <div class="pathway-step" data-step="2">2. IDE Application</div>
                        <div class="pathway-step" data-step="3">3. Clinical Trials</div>
                        <div class="pathway-step" data-step="4">4. Submission (PMA / HDE)</div>
                        <div class="pathway-step" data-step="5">5. Post-Market</div>
                    </div>
                    <div id="pathway-details">
                        <p class="italic">Hover over a step to see details.</p>
                    </div>
                </div>
            </section>

            <section id="market" class="fade-in">
                <h2>6. Market Dynamics: U.S. & Global View</h2>
                 <p style="color: var(--muted); text-align: center; max-width: 80%; margin: 16px auto 0;">The pediatric CHD device market is a significant niche within the broader cardiovascular space, dominated by large strategics who are likely acquirers for de-risked startups.</p>
                <div class="grid grid-cols-1 lg:grid-cols-2 gap-6 mt-8 items-start" style="display:grid; gap:24px;">
                    <div>
                        <h3>U.S. Pediatric PV Market Snapshot (2025)</h3>
                         <div class="kpi-grid">
                            <div class="kpi-card">
                                <p class="kpi-label">Realized Device Revenue</p>
                                <p class="kpi-value">$55–75M</p>
                            </div>
                            <div class="kpi-card">
                                <p class="kpi-label">Strategic TAM (Premium Scenario)</p>
                                <p class="kpi-value">~$133M</p>
                            </div>
                        </div>
                        <div class="callout">
                           <p style="font-size:13px; line-height:1.5;"><strong>Note on Market Sizing:</strong> The KPI cards show the U.S. market for pediatric pulmonary valves. The chart below illustrates the projected growth of the *global* market for this segment. <span class="citation">(Primary: Executive Brief; Top-Down Analysis)</span></p>
                        </div>
                        <div class="chart-container">
                            <canvas id="marketGrowthChart"></canvas>
                        </div>
                    </div>
                     <div>
                        <h3>Key Players & Investment</h3>
                        <div class="space-y-6">
                            <div>
                                <h4 class="font-semibold text-lg">Potential Acquirers (Incumbents)</h4>
                                <p class="mt-1">Medtronic and Edwards Lifesciences control the majority of the market. Their strategy is typically to partner with or acquire startups after they achieve key de-risking milestones (e.g., successful Early Feasibility Study). <span class="citation">(Primary: LSEG/CapIQ fact sheets; IBIS industry; Secondary: All Notes)</span></p>
                            </div>
                             <div>
                                <h4 class="font-semibold text-lg">Venture Groups & Funding</h4>
                                <p class="mt-1">Specialized VCs like Broadview Ventures are active in the space. However, much of the early-stage funding is non-dilutive, coming from NIH SBIR grants and foundations, which is critical for pre-clinical and early clinical development.</p>
                            </div>
                            <div>
                                <h4 class="font-semibold text-lg">Exits & Comps</h4>
                                <p class="mt-1">Valuations for clinical-stage companies with differentiated tech can range from $200-500 million. Commercial-stage companies can achieve 8-15x revenue multiples. The recent FDA approval of Renata Medical's Minima™ stent is a significant positive signal for the investment climate.</p>
                            </div>
                        </div>
                    </div>
                </div>
            </section>
        </main>
        <footer>
            <p>© 2025 Osprey Intel LLC. All rights reserved.</p>
            <p style="font-size: 11px; margin-top: 8px;">This interactive report is designed to provide a clear overview of the market landscape based on the available sources. For investment decisions, we encourage a thorough diligence process with your financial and clinical advisors.</p>
        </footer>
    </div>
<script>
    const companyData = [
        { name: 'Renata Medical', technology: 'Minima™ growth-accommodating stent for infant coarctation & PA stenosis. <span class="citation">(Primary: FDA/company press; Secondary: All Notes 9.2.2025)</span>', status: 'Approved', type: 'Stent', funding: 'Round in 2024 (details undisclosed).', background: 'Pediatric-first innovator with recent FDA approval, signaling strong market validation.' },
        { name: 'Autus Valve Technologies', technology: 'Size-adjustable (12-22mm) synthetic pulmonary valve. Surgically implanted, later expanded via balloon. <span class="citation">(Primary: ClinicalTrials.gov NCT05006404; FDA Breakthrough notice; Secondary: Conduits Report, lines 17–19)</span>', status: 'Clinical', type: 'Valve', funding: '~$325k (NIH + equity/debt).', background: 'FDA Breakthrough Designation (2023). Founders are leading pediatric surgeons/engineers. Currently in Early Feasibility Study.' },
        { name: 'Annoviant', technology: 'TxGuard™ tissue-engineered valved conduit designed to be regenerative and growth-capable. <span class="citation">(Primary: NIH SBIR awards; Annoviant preclinical report; Secondary: Annoviant Profile)</span>', status: 'Pre-clinical', type: 'Conduit', funding: '>$5M non-dilutive (NIH SBIR Phase II/IIb).', background: 'Strong pre-clinical data in large animals showing growth. Academic founders with a focus on regenerative medicine.' },
        { name: 'PolyVascular', technology: 'Polymer transcatheter pulmonary valve for RVOT replacement, aiming to defer initial surgery. <span class="citation">(Primary: Company/PitchBook docs; Secondary: All Notes 9.2.2025)</span>', status: 'Pre-clinical', type: 'Valve', funding: 'Non-dilutive + seed funding.', background: 'Supported by Texas Pediatric Device Consortium. Developing a minimally invasive solution for very young patients.' },
        { name: 'Peca Labs', technology: 'Valved shunt and polymeric valves for HLHS palliation (Stage-1 optimization). <span class="citation">(Primary: PitchBook Peca; Secondary: All Notes 9.2.2025)</span>', status: 'Clinical', type: 'Valve', funding: '>$20M venture funding.', background: 'University spinout with a focus on single-ventricle physiology. Has Humanitarian Use Device (HUD) focus.' },
        { name: 'Starlight Cardiovascular', technology: 'Neonatal ductus stent system for maintaining PDA in ductal-dependent lesions. <span class="citation">(Primary: Company case write-ups; Secondary: Company Watchlist)</span>', status: 'Clinical', type: 'Stent', funding: 'Seed + hospital grants.', background: 'KOL-backed with compassionate use cases documented. Addresses a critical neonatal need.' },
        { name: 'Sibel Health', technology: 'ANNE™ One wearable platform for post-op monitoring to enable early discharge. <span class="citation">(Primary: Sibel press/510(k); Secondary: Company Watchlist)</span>', status: 'Approved', type: 'Enabler', funding: 'Series C (~$30M).', background: '510(k)-cleared modules. Deployed in commercial pilots at leading children\'s hospitals. An enabling technology for the ecosystem.' },
        { name: 'Xeltis', technology: 'Bioresorbable polymer conduits and valves aiming for endogenous tissue restoration (ETR).', status: 'Clinical', type: 'Conduit', funding: 'Significant venture funding (e.g., €45M Series C in 2017).', background: 'A pioneer in the ETR space with long-term clinical data showing promise in creating "living" implants.' }
    ];

    const companyGrid = document.getElementById('company-grid');
    const filterBtns = document.querySelectorAll('.filter-btn');

    const renderCompanies = (filter = 'all') => {
        companyGrid.innerHTML = '';
        const filteredCompanies = companyData.filter(company => {
            if (filter === 'all') return true;
            if (filter === 'Approved') return company.status === 'Approved';
            if (filter === 'Clinical') return company.status === 'Clinical';
            if (filter === 'Pre-clinical') return company.status === 'Pre-clinical';
            return company.type === filter;
        });

        filteredCompanies.forEach(company => {
            let statusStyle = '';
            switch (company.status) {
                case 'Approved': statusStyle = 'background-color: #dcfce7; color: #166534;'; break;
                case 'Clinical': statusStyle = 'background-color: #dbeafe; color: #1e40af;'; break;
                case 'Pre-clinical': statusStyle = 'background-color: #fef3c7; color: #92400e;'; break;
            }
            const card = `
                <div class="company-card">
                    <div style="display: flex; justify-content: space-between; align-items: flex-start;">
                        <h4 style="font-weight: 700; font-size: 18px; color: var(--ink); margin: 0 16px 0 0;">${company.name}</h4>
                        <span class="status-badge" style="${statusStyle}">${company.status}</span>
                    </div>
                    <p style="margin-top: 8px; flex-grow: 1;"><strong style="font-weight: 600;">Technology:</strong> ${company.technology}</p>
                    <div style="margin-top: 16px; padding-top: 16px; border-top: 1px solid var(--line);">
                        <p style="font-size: 13px; color: var(--muted);"><strong style="font-weight: 600; color: var(--ink);">Funding:</strong> ${company.funding}</p>
                        <p style="font-size: 13px; margin-top: 8px; color: var(--muted);"><strong style="font-weight: 600; color: var(--ink);">Background:</strong> ${company.background}</p>
                    </div>
                </div>
            `;
            companyGrid.innerHTML += card;
        });
    };

    filterBtns.forEach(btn => {
        btn.addEventListener('click', () => {
            filterBtns.forEach(b => b.classList.remove('filter-btn-active'));
            btn.classList.add('filter-btn-active');
            renderCompanies(btn.dataset.filter);
        });
    });

    const pathwaySteps = document.querySelectorAll('.pathway-step');
    const pathwayDetails = document.getElementById('pathway-details');
    const pathwayData = {
        1: "Bench and animal testing to establish initial safety, biocompatibility, and device reliability.",
        2: "An Investigational Device Exemption (IDE) application is submitted to the FDA to get approval for starting human clinical trials.",
        3: "Pivotal studies in humans to collect robust data on safety and effectiveness. Small sample sizes are a key challenge in pediatrics.",
        4: "Submission of all data. The **PMA** (Premarket Approval) is the most stringent path. The **HDE** (Humanitarian Device Exemption) is for rare conditions (<8,000 patients/year in US) and is a key pathway for pediatric devices. <span class='citation'>(Primary: FDA HDE program doc; Secondary: Pipeline Strategy note)</span>",
        5: "Required long-term follow-up to monitor device durability, growth accommodation, and long-term safety in a real-world setting."
    };
    pathwaySteps.forEach(step => {
        step.addEventListener('mouseenter', () => {
            pathwayDetails.innerHTML = `<p>${pathwayData[step.dataset.step]}</p>`;
        });
    });

    const createMarketGrowthChart = () => {
        const ctx = document.getElementById('marketGrowthChart').getContext('2d');
        const rootStyles = getComputedStyle(document.documentElement);
        new Chart(ctx, {
            type: 'line',
            data: {
                labels: ['2025', '2027', '2029', '2031', '2033', '2035'],
                datasets: [{
                    label: 'Global Pediatric PV Market ($M)',
                    data: [325, 390, 470, 560, 650, 700],
                    borderColor: rootStyles.getPropertyValue('--accent').trim(),
                    backgroundColor: 'rgba(37, 99, 235, 0.1)',
                    fill: true,
                    tension: 0.3,
                    pointBackgroundColor: rootStyles.getPropertyValue('--accent').trim(),
                    pointBorderColor: '#fff',
                    pointHoverBackgroundColor: '#fff',
                    pointHoverBorderColor: rootStyles.getPropertyValue('--accent').trim()
                }]
            },
            options: {
                responsive: true, maintainAspectRatio: false,
                plugins: { 
                    legend: { display: false }, 
                    title: { display: true, text: 'Global Pediatric PV Market Growth ($M)', color: 'var(--muted)', padding: { bottom: 10 }},
                    tooltip: { callbacks: { label: (c) => `$${c.raw} Million` } } 
                },
                scales: { 
                    y: { 
                        ticks: { callback: (v) => `$${v}M`, color: rootStyles.getPropertyValue('--muted').trim() },
                        grid: { color: rootStyles.getPropertyValue('--line').trim() }
                    },
                    x: {
                        ticks: { color: rootStyles.getPropertyValue('--muted').trim() },
                        grid: { display: false }
                    }
                }
            }
        });
    };

    const navLinks = document.querySelectorAll('.nav-link');
    const sections = document.querySelectorAll('main section');
    const onScroll = () => {
        let currentSectionId = '';
        
        sections.forEach(section => {
            const sectionTop = section.offsetTop;
            if (window.scrollY >= sectionTop - 100) {
                currentSectionId = section.getAttribute('id');
            }
        });

        navLinks.forEach(link => {
            link.classList.remove('nav-link-active');
            if (link.getAttribute('href') === `#${currentSectionId}`) {
                link.classList.add('nav-link-active');
            }
        });
    };

    window.addEventListener('scroll', onScroll, { passive: true });

    document.addEventListener('DOMContentLoaded', () => {
        renderCompanies();
        createMarketGrowthChart();
        onScroll();
    });
</script>
</body>
</html>
